Anirban Maitra, Scientific Director of Sheikh Ahmed Center for Pancreatic Cancer Research and Professor of Pathology and Translational Molecular Pathology at The University of Texas MD Anderson Cancer Center, shared a post on X:
“7% of neuroendocrine tumors (including 45% of duodenal NETs and 13% of pancreatic NETs) express GLP-1R, per
Po Hien Ear and Andrew Bellizzi:
Variable GLP-1 receptor expression across diverse neuroendocrine neoplasms: implications for incretin therapies.
2nd paper from Po Hien Ear:
GLP-1R agonist promotes proliferation of neuroendocrine neoplasm cells expressing GLP-1 receptors.
These studies merit interrogation of large GLP-1 cohorts to identify if a signal of increased NETs exists, given the denominator.”
Title: Variable GLP-1 receptor expression across diverse neuroendocrine neoplasms: implications for incretin therapies.
Authors: Po Hien Ear, Sophia A Hueser, Reese E Townsend, Jessica E Maxwell, Ellen Abusada, Carlos H F Chan, Dawn E Quelle, Joseph S Dillon, James R Howe, and Andrew M Bellizzi
Read the full article.
Title: GLP-1R agonist promotes proliferation of neuroendocrine neoplasm cells expressing GLP-1 receptors.
Authors: Jonathan S. Shilyansky, Casandro J. Chan, Sophia Xiao, Irena Gribovskaja-Rupp, Dawn E. Quelle, James R. Howe, Joseph S. Dillon, Po Hien Ear
Read the full article.
Read more posts featuring Anirban Maitra on OncoDaily.